2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Monoclonal Antibody Therapy, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

630 Sustained MRD negativity for ≥24 months offsets high-risk biology in multiple myeloma through distinct tumor and immune programs

Jieqiong Zhou, PhD, David E. Mery, PhD2, Carolina D Schinke, MD3, Guido Tricot, MD/PhD4, John D Shaughnessy, Jr, PhD5, Eric Siegel, MS6, Clyde Bailey, BS7, Sharmilan Thanendrarajan, MD8, Maurizio Zangari, MD9, Yan Cheng, PhD10, Hongwei Xu, MD11, Frits van Rhee, MD, PhD12, Fenghuang Zhan, MD/PhD13
1 University of arkansas for medical sciences, Little Rock, Arkansas, United States
2 University of arkansas for medical sciences, Little Rock, United States
3 University of arkansas for medical sciences, Little Rock, Arkansas, United States
4 University of arkansas for medical sciences, Little Rock, Arkansas, United States
5 University of arkansas for medical sciences, Little Rock, Arkansas, United States
6 University of arkansas for medical sciences, Little Rock, Arkansas, United States
7 University of arkansas for medical sciences, Little Rock, Arkansas, United States
8 University of arkansas for medical sciences, Little Rock, Arkansas, United States
9 University of arkansas for medical sciences, Little Rock, Arkansas, United States
10 University of arkansas for medical sciences, Little Rock, Arkansas, United States
11 University of arkansas for medical sciences, Little Rock, Arkansas, United States
12 University of arkansas for medical sciences, Little Rock, Arkansas, United States
13 University of arkansas for medical sciences, Little Rock, Arkansas, United States

Background

Sustained measurable residual disease (MRD) negativity confers additional benefit in multiple myeloma (MM) outcomes, but for high-risk (HR) patients it remains unclear how long negativity must be sustained to offset baseline risk, and why only some patients achieve and sustain it.

 

Methods

We retrospectively analyzed 1,681 patients with newly diagnosed MM (NDMM) treated at UAMS since 2010; 1,269 with ≥2 MRD assessments (median 12 per patient; IQR, 6–20) were included. MRD was assessed by next-generation flow (10?5) and modeled as a time-varying exposure: the duration of each uninterrupted MRD-negative episode was calculated from the first negative to the subsequent positive assessment, and sustained negativity at 12, 24 and 36 months entered time-dependent Cox models only once that duration had elapsed, avoiding immortal time bias; a 24-month landmark analysis served as a sensitivity analysis. High risk was defined independently by GEP70 (GEP-HR) and the International Myeloma Working Group (IMWG) 2025 cytogenetics (CGS-HR). Gene expression profiles (GEPs) were available at diagnosis (n=1,681) and after treatment (n=615; CD138-selected, quality-filtered, obtained at a comparable time on therapy [median ≈10 months] and before both MRD negativity and progression). Pathways were assessed by GSEA (Hallmark) and similarity to the standard risk (SR) group was assessed by principal-component centroid distance. Transcriptomic comparisons were performed within CGS-HR patients.

 

Results

MRD status and GEP-HR were independent prognostic factors. Among patients sustaining MRD negativity ≥24 months, HR patients had an overall survival (OS) comparable to SR patients (HR, 0.89; 95% CI, 0.20–3.98; P=0.88), with no further benefit at ≥36 months (HR, 1.01; 0.43–2.38; P=0.98). By contrast, among patients sustaining negativity only ≥12 months but <24, HR patients retained significantly inferior OS (HR, 3.62; 1.71–7.66; P<0.001). Among HR patients, median OS was not reached in those who sustained MRD negativity for ≥24 months, compared with 25.3 months (95% CI, 20.4–37.0) in those who did not (P < 0.0001). Results were consistent with both HR definitions and with landmark analysis.

At baseline, HR patients who never achieved MRD negativity showed an increase in proliferative  programs (MYC and E2F targets, oxidative phosphorylation). After treatment these programs were attenuated in all groups, but the GEP70 score declined most and the centroid distance to SR was shortest in patients who subsequently sustained ≥24-month negativity. Comparing post-treatment profiles of patients who did versus did not sustain negativity revealed the interferon-alpha and interferon-gama response pathways were significantly enriched in the sustained group; because sampling preceded MRD negativity, this signal preceded the outcome.

 

Conclusions

HR patients require ≥24 months of sustained MRD negativity to reach an SR-like OS; 12 months is insufficient and should not by itself justify treatment de-escalation. Failure to achieve MRD negativity was associated with a proliferative baseline program, supporting more effective upfront therapy, whereas durability of MRD negativity was associated with interferon-driven immune activation during treatment.

Jieqiong Zhou, PhD: No relevant conflicts of interest to declare.